Details for New Drug Application (NDA): 215364
✉ Email this page to a colleague
NDA 215364 describes BUMETANIDE, which is a drug marketed by Aspiro, Gland Pharma Ltd, Hospira, Lupin Ltd, MSN, Qilu Pharm Hainan, Sagent, Teva Parenteral, West-ward Pharms Int, Amneal Pharms Co, Appco, Heritage Pharma, Rising, Rubicon, Sandoz, Taro, Upsher Smith Labs, and Zydus Pharms, and is included in nineteen NDAs. It is available from twenty-eight suppliers. Additional details are available on the BUMETANIDE profile page.
The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the bumetanide profile page.
The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the bumetanide profile page.
Summary for 215364
| Tradename: | BUMETANIDE |
| Applicant: | Msn |
| Ingredient: | bumetanide |
| Patents: | 0 |
Pharmacology for NDA: 215364
| Physiological Effect | Increased Diuresis at Loop of Henle |
Medical Subject Heading (MeSH) Categories for 215364
Suppliers and Packaging for NDA: 215364
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BUMETANIDE | bumetanide | INJECTABLE;INJECTION | 215364 | ANDA | Cardinal Health 107, LLC | 55154-1527 | 55154-1527-5 | 5 VIAL in 1 BAG (55154-1527-5) / 4 mL in 1 VIAL |
| BUMETANIDE | bumetanide | INJECTABLE;INJECTION | 215364 | ANDA | Novadoz Pharmaceuticals LLC | 72205-101 | 72205-101-07 | 10 VIAL in 1 CARTON (72205-101-07) / 4 mL in 1 VIAL (72205-101-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 0.25MG/ML | ||||
| Approval Date: | Aug 4, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
